[{"Assets_0_Q2_USD":339778000.0,"CommonStockSharesOutstanding_0_Q2_shares":43188012.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-40265000.0,"NetIncomeLoss_1_Q2_USD":-22219000.0,"NetIncomeLoss_2_Q2_USD":-43575000.0,"StockholdersEquity_0_Q2_USD":279336000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":7677000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":15146000.0,"Ticker":"NTLA","CIK":"1652130","name":"INTELLIA THERAPEUTICS, INC.","OfficialName":"Intellia Therapeutics Inc. Common Stock","form":"10-Q","period":"20180630","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"4259315236.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20180801"}]